Plasminogen activator inhibitor-type I: its plasma determinants and relation with cardiovascular risk

被引:106
作者
Hoekstra, T
Geleijnse, JM
Schouten, EG
Kluft, C
机构
[1] Univ Wageningen & Res Ctr, Div Human Nutr, NL-6700 EV Wageningen, Netherlands
[2] TNO Prevent & Hlth, Gaubius Lab, Leiden, Netherlands
关键词
PAI-I; determinants; review;
D O I
10.1160/TH03-08-0546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The habitual level of PAI-I is influenced by many factors, of which obesity and insulin resistance are the most important. It is possible to reduce plasma PAI-I by changes in life style, e.g. weight reduction and physical activity. Data on potential interactions between environmental and metabolic variables on one hand, and the 4G/5G-polymorphism on the other hand, are still scarce. It becomes more and more clear that PAI-I may possibly not be a major (causal) factor in cardiovascular disease, but its role in inflammation deserves further attention. In the presence of the 4G-allele not only the PAI-I response was more pronounced, but also the response of other acute-phase reactants, which implies that the increases of these reactants are secondary to the increase in PAI-I.A myocardial infarction also provokes an acute phase response. It can thus be hypothesized that the 4G-allele might exacerbate tissue injury during the acute phase after a myocardial infarction, and thereby negatively affect the prognosis.
引用
收藏
页码:861 / 872
页数:12
相关论文
共 174 条
[1]   Plasminogen activator inhibitor 1, transforming growth factor-β1, and BMI are closely associated in human adipose tissue during morbid obesity [J].
Alessi, MC ;
Bastelica, D ;
Morange, P ;
Berthet, B ;
Leduc, I ;
Verdier, M ;
Geel, O ;
Juhan-Vague, I .
DIABETES, 2000, 49 (08) :1374-1380
[2]   Fat cell function and fibrinolysis [J].
Alessi, MC ;
Morange, P ;
Juhan-Vague, I .
HORMONE AND METABOLIC RESEARCH, 2000, 32 (11-12) :504-508
[3]   Circadian patterns of plasma t-PA and PAI-1 antigen levels in patients with severe peripheral atherosclerosis [J].
Andreotti, F ;
Prevost, R ;
Lupi, A ;
Hamilton, J ;
deBart, ACW ;
Huisman, LGM ;
Maseri, A ;
Kluft, C .
FIBRINOLYSIS, 1996, 10 :159-160
[4]   DIURNAL-VARIATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ITS RAPID INHIBITOR (PAI-1) [J].
ANGLETON, P ;
CHANDLER, WL ;
SCHMER, G .
CIRCULATION, 1989, 79 (01) :101-106
[5]   Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1 [J].
Aso, Y ;
Matsumoto, S ;
Fujiwara, Y ;
Tayama, K ;
Inukai, T ;
Takemura, Y .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (04) :471-476
[6]   Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects [J].
Bastard, JP ;
Vidal, H ;
Jardel, C ;
Bruckert, E ;
Robin, D ;
Vallier, P ;
Blondy, P ;
Turpin, G ;
Forest, C ;
Hainque, B .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (01) :70-74
[7]  
Bastard JP, 2000, DIABETES-METAB RES, V16, P192, DOI 10.1002/1520-7560(200005/06)16:3<192::AID-DMRR114>3.0.CO
[8]  
2-G
[9]   Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat - Evidence of differences between visceral and subcutaneous deposits [J].
Bastelica, D ;
Morange, P ;
Berthet, B ;
Borghi, H ;
Lacroix, O ;
Grino, M ;
Juhan-Vague, I ;
Alessi, MC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (01) :173-178
[10]   Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction [J].
Bloemenkamp, KWM ;
de Maat, MPM ;
Dersjant-Roorda, MC ;
Helmerhorst, FM ;
Kluft, C .
VASCULAR PHARMACOLOGY, 2002, 39 (03) :131-136